JW0104+C2403

Phase 3Small molecule

JJW Pharmaceutical

JW0104+C2403 is one of 26 small molecule programs targeting Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypertensionActive, not recruiting

HypertensionPhase 3

Active, not recruiting

Competition

Competitive Landscape

566 competitors in Hypertension

#DrugCompanyPhaseTrials

Apresoline

Novartis

Preclinical

7 2

Zebeta

Teva

Preclinical

6 3

Edarbi

Takeda

Preclinical

4 4

JW0104+C2403

JJW Pharmaceutical

Phase 3

1 5

Aceon

Institut de Recherches Internationales Servier

Preclinical

5 6

Alphagan

Winrevair

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 9

Disalcid

JJoslin Diabetes Center

Preclinical

1 10

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypertension1 trial

Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

Recruiting·JJW Pharmaceutical·Phase 3·NCT06643130·162 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for JW0104+C2403. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JW0104+C2403 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JW0104+C2403. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — JW Pharmaceutical company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJW Pharmaceutical

JW0104+C2403

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypertension1 trial

References

Drug Info

Quick Facts

Related News